Navigation Links
Octapharma USA to Participate in Important Medical Meetings at AABB, NHF, ASHP and ASH
Date:10/18/2011

problems may affect intimacy decisions, communication styles that promote intimacy and honesty, and disclosure.

NHF has also accepted three Octapharma research clinical posters entitled:

  • "Immune Tolerance Therapy (ITI) in Children with FVIII Inhibitors: Cost of care analysis comparison with NovoSeven in the treatment of hemophilia A patients with inhibitors,"
  • "ITI with a VWF/FVIII Concentrate in Haemophilia A Patients with Inhibitors and a Poor Prognosis for ITI Success: Progress Report on Octanate in the ObsITI Study," and
  • "ADAMTS 13 in Von Willebrand Factor (VWF) Concentrates: Is an Intact VWF Triplet Structure Important for VWF Function?"

At AABB in October, Octapharma USA will have a clinical trials booth where medical/clinical staff will be available to meet with investigators interested in participating in the various clinical trials on display, including:

  • "Prospective, Open-Label, Multi-Center, Phase III Clinical Study to Investigate the Efficacy and Safety of Human Factor VWF/FVIII Concentrate (Wilate) in Subjects With Inherited Von Willebrand Disease Who Undergo Major Surgical Procedures,"
  • "A Randomized, Open Label, Efficacy and Safety Study of OCTAPLEX and Fresh Frozen Plasma (FFP) in Patients Under Vitamin k Antagonist Therapy With the Need for Urgent Surgery or Invasive Procedures," and
  • "Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Human-cl rhFVIII, a Newly Developed Human Cell-line Derived Recombinant FVIII Concentrate in Previously Treated Patients With Severe Hemophilia A."

For more information on the clinical trials, please visit www.clinicaltrials.gov.  Additionally, Octapharma USA is also planning a special meeting during AABB with key opinion leaders to discuss the viability of introdu
'/>"/>

SOURCE Octapharma USA
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company Octapharma
2. Octapharma Accepting Applications for Research Grants on Immunotherapy, Coagulation Disorders and Critical Care
3. Octapharma Targeting the Major Risk of Hemophilia Treatment - FVIII Antibodies
4. Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease
5. Octapharma Group and Fresenius Kabi Enter Into an Exclusive License, Development and Supply Agreement for a HESylated Recombinant Protein
6. Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specifically for von Willebrand Disease
7. Octapharma USA Announces Availability and Distributors for wilate®, the First Replacement Therapy Developed Specifically for von Willebrand Disease
8. FDA Confirms Orphan Drug Exclusivity Approval for wilate®, Octapharma USAs New Therapy for Common Inherited Bleeding Disorder
9. Octapharma USA Launches Web Resource for von Willebrand Disease Healthcare Professionals and Patients
10. Octapharma Accepting Applications for Research Grants Focused on Human Protein Therapies
11. Octapharma Clinical Trial Begins in the U.S. and Germany Treating Hemophilia A Patients with First Recombinant Factor VIII Derived from a Human Cell-Line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/256szd/corporate ... Reputation of Pharma in 2014 - a Perspective of ... to their offering. For the first time, ... corporate reputation of the pharmaceutical industry held by patient ... views of patient organisations representing all therapy areas. ...
(Date:4/17/2015)... -- Bionomics Limited (ASX:BNO, ADR:BMICY), a biopharmaceutical company focused ... the treatment of cancer and diseases of the central ... three of its most advanced oncology programs at the ... Annual Meeting being held from April 18-22, 2015 ... The presentation on the BNC105 program describes ...
(Date:4/16/2015)... Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ), a ... products for the treatment of central nervous system disorders, ... quarter of 2015 on Wednesday, May 6, 2015, after ... host a conference call at 4:30 PM ET on ... discuss the first quarter 2015 financial results and other ...
Breaking Medicine Technology:Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition 2Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition 3Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting 2Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting 3Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting 4Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting 5Vanda Pharmaceuticals to Announce First Quarter 2015 Financial Results on May 6, 2015 2
(Date:4/17/2015)... Enthusiasts of gourmet cuisine and beverages will ... 2015. The event will be held in the heart of ... Ave NW, Grand Rapids, MI 49503) and will feature wine ... Patrons are encouraged to savor the food and beverage pairings ... year’s event will feature seven chefs, including:, ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 Baptist Health ... have signed a partnership agreement designed to transform oncology ... The institutions have agreed to create a joint cancer ... protocols and translational research. Baptist MD Anderson Cancer Center ... providing a single destination for highly coordinated, multidisciplinary cancer ...
(Date:4/17/2015)... 17, 2015 Calvary Hospital recently announced Timothy ... Executive Vice President on May 11. The Fund directs all ... mission. Barr succeeds Vincent J. Spinelli, who retired several months ... take on and supervise the important work that the Fund ... “As Calvary continues to expand and bring our signature care ...
(Date:4/17/2015)... Nomedexamlifeinsurance.com has released a new blog post explaining how ... , Smoking is linked to numerous diseases like cancer ... smokers more money for life insurance plans. Someone who ... can qualify for advantageous offers. , The life ... non-smokers. Comparing quotes is the best method of reducing ...
(Date:4/17/2015)... Verndale, a Global Experience Technology Company, ... been chosen as a Boston Business Journal (BBJ) Pacesetter, ... the region. The BBJ’s Pacesetters represents privately held businesses ... 2014. This is the eighth consecutive year and the ... has been honored with this award. , “Being honored ...
Breaking Medicine News(10 mins):Health News:Children’s Leukemia Foundation of Michigan Presents 3rd Annual CRUSH Grand Rapids 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 3Health News:Timothy P. Barr Appointed Executive Vice President of Calvary Fund 2Health News:Timothy P. Barr Appointed Executive Vice President of Calvary Fund 3Health News:Life Insurance Quotes for Smokers Available Online 2Health News:Verndale Honored as 2015 Boston Business Journal Pacesetter, Named 46th Fastest Growing Private Company 2
... BioFit Engineered Products, an Ohio-based manufacturer and long-standing leader in ... and Atmospheric Administration (NOAA) with a solution to a unique ... habitat. , ... Bowling Green, OH ...
... expansion of its Sealy office. , ... Sealy, Texas (PRWEB) January 8, ... Sealy office. Located on Meyer Street the five-year old-practice has blossomed reaching ... of the surrounding communities as well., , , , ,The eye ...
... Service Employees,International Union (SEIU) announced the formation of the ... the patients that they serve,a greater voice as we ... nation,s,history. , Since adoption of ... made,numerous jurisdiction decisions that have helped members who do ...
... Internacional, S.A.B. de C.V. (BMV: LAB) ("Genomma Lab" ... and personal care products company announced that on January ... stock repurchase fund according to the terms approved by ... up to Ps. 100 million pesos. Company Description ...
... EXTON, Pa., Jan. 9 Kensey Nash Corporation (Nasdaq: ... release its earnings results for its second quarter ended ... Wednesday, January 28, 2009. Joe Kaufmann, President and ... results on Wednesday, January 28, 2009 at 9:00 A.M. ...
... study found, , , FRIDAY, Jan. 9 (HealthDay News) -- If ... cut your risk of dying from flu in half, research ... perfect match for the strains circulating in any given year, ... that included 10 flu seasons, worth of data also found ...
Cached Medicine News:Health News:BioFit 1Y Takes the Plunge to Fill Undersea Seating Role for NOAA 2Health News:Austin County Eye Expands Sealy Eye Clinic Office 2Health News:Statement From SEIU International President Andy Stern on UHW Leaders' Response to the Jurisdiction Decision 2Health News:Kensey Nash Corporation Announces Its Second Quarter 2009 Earnings Release Date and Teleconference 2Health News:You're Never Too Old for a Flu Shot 2Health News:You're Never Too Old for a Flu Shot 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: